
Aclarion Inc (ACON) Stock Forecast & Price Target
Aclarion Inc (ACON) Analyst Ratings
Bulls say
Aclarion is a commercial-stage healthcare technology company that uses AI-driven imaging technology to optimize clinical treatment of lower back and neck pain, and its recent issuance of a new US patent regarding pain assessment using MRS data adds to its significant portfolio of patents. The company is experiencing strong commercial momentum and has formed partnerships with multiple clinics and healthcare providers, which is reflected in its rising revenues. Despite some risks, including a recent increase in operating expenses, Aclarion has a strong balance sheet with over $20 million in cash, positioning it well for future growth and commercialization of its product.
Bears say
Aclarion is experiencing an expansion in share count which has resulted in a better-than-expected EPS for Q1 FY26. However, despite an 11% increase in revenue and higher Nociscan report volume, the company's operating expenses have also significantly increased due to investments in sales, R&D, and IR. The lack of forward guidance also raises concerns about the company's future profitability and growth potential.
This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.
Aclarion Inc (ACON) Analyst Forecast & Price Prediction
Start investing in Aclarion Inc (ACON)
Order type
Buy in
Order amount
Est. shares
0 shares